{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-045204","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.998111+00:00","generated_at":"2026-05-16T13:30:27.501006+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Roivant accelerates key pipeline timelines; Immunovant raises $550M","bullets":["Brepocitinib NDA filing in dermatomyositis expected early 2026; commercial launch early 2027.","Phase 3 brepocitinib trial in non-infectious uveitis fully enrolled; topline data now H2 2026.","Brepocitinib proof-of-concept in cutaneous sarcoidosis fully enrolled; topline data now H1 2026.","IMVT-1402 potentially registrational trial in D2T RA topline data now expected CY 2026.","Immunovant financing led by Roivant generated ~$550M gross proceeds, extending cash runway to IMVT-1402 launch in GD."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-045204","json":"https://secwatch.observer/filing/0001140361-25-045204.json","markdown":"https://secwatch.observer/filing/0001140361-25-045204.md","text":"https://secwatch.observer/filing/0001140361-25-045204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045204/0001140361-25-045204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045204/ef20061071_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:30:27.501006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}